It was an impressive turnaround on Tuesday for the stock market as, after Monday’s drop, the short-term momentum appeared to be turning negative. Of course, to keep the positive “Mo” going, we need to see further gains Wednesday. A drop back below Monday’s lows will turn the focus back on the downside.The S&P futures are flat in early trading and […]
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called “patent cliff.” Driving this point home, the closely watched iShares Nasdaq Biotechnology Index has appreciated a princely 162% since 2012:As earnings across the industry are […]
LONDON, November 24, 2014 /PRNewswire/ –Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 21, 2014, the NASDAQ Composite ended at 4,712.97, […]
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth:
China cut interest rates unexpectedly on Friday, stepping up efforts to support the world’s second-biggest economy as it heads towards its slowest expansion in nearly a quarter of a century.The cut, the first in over two years, came as factory growth has stalled […]
Biotech stocks surged nicely Tuesday with the iShares Biotechnology ETF rallying more than 2 percent.For the most part, biotech stocks have performed very well over the last month and even the last year.That performance can be seen quite well with names such as Gilead Sciences, Illumina and Vertex Pharmaceuticals all having hit new highs within the last 30 days.However, not […]
View gallery.Last week’s market price action was somewhat like watching paint peel. In other words, there just wasn’t much going on.Even though the market edged higher for the fourth straight week and the S&P 500 hit new record highs, the gains came during the smallest market moves since 1979.After Monday, the benchmark S&P rose or fell less than 0.1 percent […]
Last week’s market price action was somewhat like watching paint peel. In other words, there just wasn’t much going on.Even though the market edged higher for the fourth straight week and the S&P 500 hit new record highs, the gains came during the smallest market moves since 1979.After Monday, the benchmark S&P rose or fell less than 0.1 percent on […]
View photo.Anyone who trades or invests in biotech stocks knows how volatile they can be, according to Adam Feuerstein.Feuerstein is a senior columnist for TheStreet.com, and he recently joined Benzinga’s #PreMarket Prep to talk about how he keeps track of what’s going on in the biotech sector.“I think the most important thing for investors in the biotech sector is just […]
By Ben LevisohnYes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:
October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years. We believe […]
When it comes to biotech stocks, one trait that tends to keep investors away is the same trait that attracts others: volatility.Volatility can be great when the trade goes an investor’s way, but it can also wipe out a lot of gains when that trade goes against an investor.The most common way investors measure volatility within a particular stock is […]
